- After-Shows
- Alternative
- Animals
- Animation
- Arts
- Astronomy
- Automotive
- Aviation
- Baseball
- Basketball
- Beauty
- Books
- Buddhism
- Business
- Careers
- Chemistry
- Christianity
- Climate
- Comedy
- Commentary
- Courses
- Crafts
- Cricket
- Cryptocurrency
- Culture
- Daily
- Design
- Documentary
- Drama
- Earth
- Education
- Entertainment
- Entrepreneurship
- Family
- Fantasy
- Fashion
- Fiction
- Film
- Fitness
- Food
- Football
- Games
- Garden
- Golf
- Government
- Health
- Hinduism
- History
- Hobbies
- Hockey
- Home
- How-To
- Improv
- Interviews
- Investing
- Islam
- Journals
- Judaism
- Kids
- Language
- Learning
- Leisure
- Life
- Management
- Manga
- Marketing
- Mathematics
- Medicine
- Mental
- Music
- Natural
- Nature
- News
- Non-Profit
- Nutrition
- Parenting
- Performing
- Personal
- Pets
- Philosophy
- Physics
- Places
- Politics
- Relationships
- Religion
- Reviews
- Role-Playing
- Rugby
- Running
- Science
- Self-Improvement
- Sexuality
- Soccer
- Social
- Society
- Spirituality
- Sports
- Stand-Up
- Stories
- Swimming
- TV
- Tabletop
- Technology
- Tennis
- Travel
- True Crime
- Episode-Games
- Visual
- Volleyball
- Weather
- Wilderness
- Wrestling
- Other
November Market Kick-off, J&J's $16.6B deal, Chinese Stocks Rally and Biden Blasts Big Oil "War Profiteering" 11/1/22
Carl Quintanilla, Jim Cramer and David Faber explored what investors can expect from the markets in November after a bullish October, which included the Dow's best month since January 1976. M&A also in the spotlight: Shares of Abiomed soaring after Johnson and Johnson agreed to acquire the cardio technology company in a deal valued at $16.6 billion. The anchors also discussed Chinese stocks in rally mode. Unverified posts on social media said policymakers in China are looking to relax stringent COVID rules. Also in focus: Day one of the Fed's policy meeting, President Biden accuses big oil companies of "war profiteering" and backs the idea of slapping them with a windfall tax, plus market reaction to earnings from the likes of Pfizer, Eli Lilly and Uber.